AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
VITALIZE.Use and Effectiveness of Sodium Zirconium Cyclosilicate (LokelmaTM) in the Real-world Setting in Spain
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 230
- Registration Number
- NCT06635499
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 560
- Registration Number
- NCT06635447
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Real-life Treatment Outcomes of Ravulizumab in PNH
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06633536
AZAHAR Study To Describe Anifrolumab in a Real-World Setting
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06626945
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 878
- Registration Number
- NCT06627647
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
OPTIMISE-CKD Study_current Clinical Landscape in Spain
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 86516
- Registration Number
- NCT06614712
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06611423
- Locations
- 🇸🇪
Research Site, Solna, Sweden
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT06610526
- Locations
- 🇨🇳
Research Site, Xian, China
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT06606847
- Locations
- 🇷🇺
Research Site, Ufa, Russian Federation
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
Recruiting
- Conditions
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06605885
- Locations
- 🇨🇳
Research Site, Zhuhai, China
© Copyright 2024. All Rights Reserved by MedPath